Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Breakthrough Therapies Becoming Breakthrough Applications For Tezacaftor, Burosumab, Emicizumab

Executive Summary

The latest regulatory submission news and highlights from our US FDA Performance Tracker.


Related Content

Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
Keeping Track: A Second Straight Burst Of FDA Approvals
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Vertex Triple-Data Combos Live Up To High Hopes In Early Studies
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts